News coverage about Ekso Bionics (NASDAQ:EKSO) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ekso Bionics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.0477695712339 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment’s scoring:

EKSO has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Ekso Bionics from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Thursday, September 7th. ValuEngine upgraded Ekso Bionics from a “strong sell” rating to a “sell” rating in a research note on Friday, November 17th.

Ekso Bionics (NASDAQ:EKSO) traded down $0.39 during trading on Wednesday, hitting $2.52. The company had a trading volume of 1,714,986 shares, compared to its average volume of 885,721. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.09 and a quick ratio of 5.73. Ekso Bionics has a 12-month low of $0.99 and a 12-month high of $4.90.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Wednesday, November 8th. The company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.05). Ekso Bionics had a negative return on equity of 323.00% and a negative net margin of 343.53%. The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $2.40 million. equities analysts anticipate that Ekso Bionics will post -0.81 EPS for the current fiscal year.

In related news, insider Russ Angold sold 50,000 shares of Ekso Bionics stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $3.51, for a total transaction of $175,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased 41,264 shares of company stock valued at $48,255 in the last ninety days. Corporate insiders own 7.10% of the company’s stock.

WARNING: “Ekso Bionics (EKSO) Earning Somewhat Positive Media Coverage, Study Finds” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Insider Buying and Selling by Quarter for Ekso Bionics (NASDAQ:EKSO)

Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with's FREE daily email newsletter.